Mural Oncology shareholders approve acquisition by XRA 5 Corp.

Mural Oncology (MURA) announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty (XOMA). As described in more detail below, a majority in number of the shareholders of record present and voting, either in person or by proxy and more than 99% of the votes cast at both a scheme meeting of shareholders and an extraordinary general meeting of shareholders, both held on October 24 in Dublin, Ireland, were in favour of the transaction, representing in respect of the Scheme Meeting, approximately 58% of the shares outstanding and eligible to be voted at the Scheme Meeting and in respect of the EGM, approximately 61% of the shares outstanding and eligible to be voted at the EGM.